Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Inesh Sood | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Inesh Sood | Medicine and Dentistry | Best Researcher Award

Research Intern at University of Oxford | United Kingdom

Mr. Inesh Sood is an accomplished medical scholar and emerging researcher from the University of Oxford, whose work bridges medicine, neuroscience, and technological innovation. With a First-Class Honours degree in Medical Sciences and ongoing studies toward the Bachelor of Medicine and Bachelor of Surgery, he has consistently demonstrated academic excellence, earning top distinctions and merit-based scholarships. His education has been characterized by a rigorous engagement with clinical sciences, biomedical research, and leadership in academic societies, notably through his service as Vice-President of a prominent medical society at Oxford. Professionally, he has contributed to cutting-edge research projects within the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, where he evaluated the application of artificial intelligence scribes in clinical consultations, exploring how technology can enhance medical efficiency and patient care. In parallel, his work with the Bajo Lorenzana Auditory Neuroscience Group focuses on the optogenetic activation of neuronal pathways, where he developed MATLAB-based analytical tools to assess and classify neuronal activity from live recordings an initiative that demonstrates his technical proficiency and innovative approach to neuroscience research. His findings are being presented at the prestigious Society for Neuroscience (SFN) conference, underscoring his growing recognition within the global scientific community. Earlier, as a visiting scholar at Brown University, he conducted molecular and cell biology research on germline migration using CRISPRCAS9 techniques and single-cell sequencing analysis, contributing to publications in developmental biology. Beyond his laboratory expertise, he has also engaged in healthcare consulting, applying analytical and strategic thinking to support biotech innovation in cancer vaccine development. His diverse skill set spans biomedical research, data analysis, and leadership in academic and collaborative settings. Mr.Inesh Sood’s research interests lie in medical innovation, neuroscience, and the intersection of artificial intelligence with healthcare systems. Through his interdisciplinary experiences, he continues to pursue a vision of advancing scientific discovery and improving patient outcomes by combining evidence-based medicine with cutting-edge technology, reflecting a commitment to excellence, curiosity, and societal impact in the field of medicine and dentistry.

Profile: Orcid | LInkedin

Featured Publications:

H., Sood,(2025).Biomarkers in Stereotactic Ablative Radiotherapy: Current Evidence and Future Directions. International Journal of Molecular Sciences, 26(21), 10640.

H., Sood,(2025).Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer. International Journal of Molecular Sciences, 26(21), 10302.

Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Dr. Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award 

Assistant professor at Beth Israel Deaconess Medical Center | United States

Dr. Zsuzsanna Zsengeller is a distinguished medical scientist whose career spans clinical medicine, molecular biology, and translational research. She has established herself as a global leader in the investigation of preeclampsia, mitochondrial dysfunction, and kidney-related disorders. With appointments at world-renowned institutions, she has advanced knowledge in gene therapy, molecular signaling, and maternal-fetal health. Her professional journey demonstrates a seamless integration of clinical insight and laboratory research, producing innovative therapeutic approaches. Through consistent scholarly output, grant leadership, and mentorship of future scientists, Dr. Zsuzsanna Zsengeller embodies excellence in academic medicine and translational science, with her work directly impacting patient health worldwide.

Profile:

Orcid

Education:

Dr. Zsuzsanna Zsengeller earned her Doctor of Medicine degree in General Medicine, followed by a Ph.D. in Medical Science with a strong foundation in microbiology. Her academic path was marked by a commitment to understanding complex disease mechanisms through both experimental and clinical approaches. Her postgraduate training included prestigious postdoctoral fellowships in pulmonary biology and respiratory diseases, where she refined her expertise in molecular and cellular biology. These academic experiences provided the groundwork for her lifelong research into oxidative stress, immune signaling, and vascular biology, ultimately shaping her into a well-recognized expert in mitochondrial and maternal health research.

Experience:

Dr. Zsuzsanna Zsengeller has extensive experience as both a clinician and scientist, having held positions across leading hospitals, research institutions, and industry collaborations. Her work includes significant contributions to pulmonary biology, renal pathology, and preeclampsia research. She has served in roles as staff scientist, senior scientist, consultant, and academic faculty member, currently serving as Assistant Professor of Medicine at Harvard Medical School. Her collaborations with multidisciplinary teams have resulted in advancements in therapeutic strategies for cardiovascular, renal, and maternal health. With experience in academia, industry, and clinical translation, she has built a unique career that bridges discovery and application.

Research Interest:

Dr. Zsuzsanna Zsengeller’s research interests center on the pathogenesis and treatment of preeclampsia, kidney disease, and mitochondrial dysfunction. She investigates redox biology, nitric oxide modulation, and oxidative stress pathways to understand how cellular signaling impacts maternal and fetal outcomes. Her translational studies have examined novel dual-function redox modulators, antioxidants, and mitochondrial-targeted therapies. Beyond maternal health, her work extends into nephrology and cardiovascular disease, with particular focus on mechanisms of APOL nephropathy and endothelial dysfunction. Through advanced molecular techniques and therapeutic modeling, her research seeks to translate laboratory discoveries into clinical strategies, offering hope for improved patient outcomes worldwide.

Awards and Honors:

Dr. Zsuzsanna Zsengeller has been recognized with numerous honors that reflect her leadership in biomedical science and translational medicine. She has received institutional research funding awards, including competitive support for her pioneering work on mitochondrial-targeted antioxidants for preeclampsia therapy. Her contributions have also been acknowledged through awards from scientific societies, highlighting her excellence in poster presentations, mentorship, and innovative project design. Her research projects have consistently received funding from federal agencies and medical foundations, underscoring the clinical relevance and impact of her work. These awards honor her as a trailblazer in developing therapies addressing urgent global health challenges.

Publications:

Title: Development of Diaryl Hydrazones for Alleviation of Mitochondrial Oxidative Stress in Preeclampsia
Year of Publication: 2025
Citation: 1

Title: Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Year of Publication: 2025
Citation: 1

Title: A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Year of Publication: 2025
Citation: 5

Title: Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2
Year of Publication: 2024
Citation: 5

Title: Solvent- and Catalyst-Free Environmentally Benign High Hydrostatic Pressure-Assisted Synthesis of Bioactive Hydrazones and the Evaluation of Their Stability Under Various Storage Conditions
Year of Publication: 2024
Citation: 3

Title: A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia—A Proof-of-Principle Study in a Murine Model
Year of Publication: 2023
Citation: 3

Title: Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury
Year of Publication: 2023
Citation: 8

Conclusion:

Dr. Zsuzsanna  Zsengeller stands as a pioneering physician-scientist whose research has transformed the understanding of oxidative stress, mitochondrial dysfunction, and maternal-fetal disorders. Her leadership in translational medicine continues to advance new therapies that address major public health burdens, particularly preeclampsia and kidney disease. Through groundbreaking research, impactful publications, and mentorship of future leaders, she exemplifies the highest standards of academic and clinical excellence. Her career demonstrates how dedication to discovery can be translated into real-world medical advancements, making her a highly deserving candidate for prestigious recognition in biomedical and clinical research innovation.